Literature DB >> 11745690

Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations.

F Al-Mulla1, E M MacKenzie.   

Abstract

The p21 proteins encoded by N-, Ki-, and H-ras are small guanine nucleotide-binding proteins that act as switches in several signal transduction pathways. Recently, evidence has been accumulating to suggest that valine-12 mutation in the Ki-Ras protein is associated with lung and colorectal tumours that are more aggressive than those carrying aspartate-12 mutation. The purpose of this study was to determine whether cells transfected with different Ki-ras codon-12 mutants have different biological behaviours in vitro that could reflect the differences in behaviour in vivo. For that reason, Rat-1 fibroblasts transfected with the valine-12 or aspartate-12 mutant or the wild-type Ki-ras gene were assessed in terms of in vitro invasion, transformation, and VEGF production. Both mutants demonstrated equal abilities to transform Rat-1 cells and induce VEGF production, while cells transfected with wild-type Ki-Ras failed to do so. Most significantly, the valine-12 mutants demonstrated a greater ability to invade Matrigel than cells expressing the aspartate-12 mutant or wild-type Ki-Ras proteins. This study complements previous experimental data that specific Ras mutations differ in their effects in vivo and shows, for the first time, a significant difference in Matrigel invasion in vitro. The precise mechanisms behind these biological differences in vivo and in vitro should now be investigated. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745690     DOI: 10.1002/path.995

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  14 in total

1.  Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.

Authors:  Takeshi Ogura; Kenji Yamao; Kazuo Hara; Nobumasa Mizuno; Susumu Hijioka; Hiroshi Imaoka; Akira Sawaki; Yasumasa Niwa; Masahiro Tajika; Shinya Kondo; Tsutomu Tanaka; Yasuhiro Shimizu; Vikram Bhatia; Kazuhide Higuchi; Waki Hosoda; Yasushi Yatabe
Journal:  J Gastroenterol       Date:  2012-09-15       Impact factor: 7.527

2.  KRAS mutation and NF-κB activation indicates tolerance of chemotherapy and poor prognosis in colorectal cancer.

Authors:  Gen Lin; Xiong-Wei Zheng; Chao Li; Qiang Chen; Yun-Bin Ye
Journal:  Dig Dis Sci       Date:  2012-04-24       Impact factor: 3.199

3.  Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.

Authors:  Helena A Yu; Camelia S Sima; Ronglai Shen; Samantha Kass; Justin Gainor; Alice Shaw; Megan Hames; Wade Iams; Jonathan Aston; Christine M Lovly; Leora Horn; Christine Lydon; Geoffrey R Oxnard; Mark G Kris; Marc Ladanyi; Gregory J Riely
Journal:  J Thorac Oncol       Date:  2015-03       Impact factor: 15.609

4.  KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Authors:  Yvonne T Tsang; Michael T Deavers; Charlotte C Sun; Suet-Yan Kwan; Eric Kuo; Anais Malpica; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  J Pathol       Date:  2013-12       Impact factor: 7.996

5.  The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer.

Authors:  Slah Ouerhani; Karim Bougatef; Ismail Soltani; Amel Ben Ammar Elgaaied; Salem Abbes; Samia Menif
Journal:  Mol Biol Rep       Date:  2013-05-03       Impact factor: 2.316

6.  Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.

Authors:  Wenbin Li; Wenxue Zhi; Shuangmei Zou; Tian Qiu; Yun Ling; Ling Shan; Susheng Shi; Jianming Ying
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

7.  Genetic and biochemical alterations in non-small cell lung cancer.

Authors:  Jackie L Johnson; Smitha Pillai; Srikumar P Chellappan
Journal:  Biochem Res Int       Date:  2012-08-15

8.  Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?

Authors:  Victoria M Villaflor; Ravi Salgia
Journal:  J Carcinog       Date:  2013-03-18

9.  Molecular detection (k-ras) of exfoliated tumour cells in the pelvis is a prognostic factor after resection of rectal cancer?

Authors:  Annette Torgunrud Kristensen; Johan N Wiig; Stein G Larsen; Karl-Erik Giercksky; Per O Ekstrøm
Journal:  BMC Cancer       Date:  2008-07-27       Impact factor: 4.430

10.  Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context.

Authors:  Massimiliano Monticone; Emanuela Biollo; Massimo Maffei; Alessandra Donadini; Francesco Romeo; Clelia Tiziana Storlazzi; Walter Giaretti; Patrizio Castagnola
Journal:  Mol Cancer       Date:  2008-12-16       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.